Member Info for Jarv55

Lol battle between the bulls and bears expect holdings rns over the next few sessions

EEZY shorter INTEREST study did not meet the Day 28 primary composite endpoint with both Traumakine and placebo reporting similar all cause mortality rates. Further investigations are currently underway to provide additional information on the outcome of the current analysis. � Japanese partner Maruishi continued to progress their pivotal Phase III ARDS trial in Japan and has received two IDMC recommendations to continue the trial as planned. Maruishi anticipates completion of recruitment of this 120-patient study in mid 2018.

More news to come "Beyond ARDS, we believe that Traumakine has excellent potential for application in other areas of organ protection. Impairment of endothelial barrier can be a reason for many organ dysfunctions. We are currently exploring its efficacy in addressing Multi-Organ Failure and mortality in patients with surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) through a Phase II trial. "We are also pleased to have made substantial progress with our novel cancer immunotherapy candidate Clevegen, which works to remove immune suppression around tumours caused by tumour associated type-2 macrophages (TAM). Following the development of our new TIET platform and the commencement of preclinical toxicity studies we are now preparing to embark upon an extensive clinical program to investigate this promising candidate. In addition to its potential application in oncology, we are excited by Clevegen's potential application in a broader range of indications including chronic infections and vaccination enhancement."

Successful over-subscribed fundraising of �15.0 million through Placing and Subscription TURKU - FINLAND, 21 February 2018 - Faron Pharmaceuticals Oy ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, is pleased to announce that, following the announcement on 16 February 2018, the proposed Placing and Subscription has been subscribed for in full, in satisfaction of the Placee Condition. Pursuant to the Placing and Subscription, the Company is raising approximately �15.0 million before expenses by way of the Placing of 1,729,350 Placing Shares and the Subscription of 134,000 Subscription Shares at the Issue Price of 805 pence per share. The Placing and Subscription have been supported by the participation of existing and new institutional shareholders. The Board of Directors of Faron has resolved on and approved the issuance of the Placing Shares and the Subscription Shares pursuant to the existing authorisation granted by shareholders at the Company's Annual General Meeting held on 16 May 2017. Very likely

People averaging down Wideyed

next wave incoming https://invst.ly/7ew6w

Currencyching 200 by tomorrow look at the bigger buys munching up the free float

Currencyching 200 by tomorrow look at the bigger buys munching up the free float

Same happened yesterday and it ended up 34% long way to go yet, hasn't even got back into the bollinger bands trading range on the daily yet 220 first target https://invst.ly/7evdz

Will the directors be buying down here?

They seem surprised by the results compared to other studies Dr Markku Jalkanen, CEO of Faron, said: "We are incredibly disappointed and surprised by these results. We need to further analyse the data in order to understand how this study differs from our previous positive results with ARDS patients, both in terms of Traumakine's efficacy, and in the unusually low mortality rate observed in the placebo arm. We look forward to the results of the Japanese study in Q3 2018 and will be considering how we can advance Traumakine in clinical development. "We will continue our plans to advance our next asset, Clevegen, our second candidate which is a ground breaking anti-Clever-1 antibody, into clinical development in solid cancers later this year. Further investigations are currently underway to provide additional information on the outcome of the current analysis

"We will continue our plans to advance our next asset, Clevegen, our second candidate which is a ground breaking anti-Clever-1 antibody, into clinical development in solid cancers later this year.

Japanese partner Maruishi continued to progress their pivotal Phase III ARDS trial in Japan and has received two IDMC recommendations to continue the trial as planned. Maruishi anticipates completion of recruitment of this 120-patient study in mid 2018.

Bought some way over sold on the chart

#Knowthegame

Well bid and bid rising

Yes it would

Nice interview

Sappire not quite sure why you are here if you are not interested in the stock, but I can say that Inft will do very well and is listing on the main market. This stock has over �1 million in the bank has a listing which is very attractive for anyone trying to back and asset or assets into it. Rumours going around of a tech deal and if that is true this is going to be cheap at this level. If you are trying to get in cheaper or working on behalf of someone who is you better come up with something better than comparing this to Inft.

Can't say I am a fan of Docs but think he is going to want more than 10% seeing as he bought at 0.25